These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Clozapine and lithium require Caenorhabditis elegans β-arrestin and serum- and glucocorticoid-inducible kinase to affect Daf-16 (FOXO) localization. Weeks KR; Dwyer DS; Aamodt EJ J Neurosci Res; 2011 Oct; 89(10):1658-65. PubMed ID: 21732403 [TBL] [Abstract][Full Text] [Related]
9. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Beaulieu JM Int J Neuropsychopharmacol; 2007 Feb; 10(1):3-6. PubMed ID: 16784549 [No Abstract] [Full Text] [Related]
10. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection. Rametti A; Esclaire F; Yardin C; Cogné N; Terro F Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787 [TBL] [Abstract][Full Text] [Related]
11. Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta). Serretti A; Drago A; De Ronchi D Curr Med Chem; 2009; 16(15):1917-48. PubMed ID: 19442155 [TBL] [Abstract][Full Text] [Related]
12. Lithium Pharmacology and a Potential Role of Lithium on Methamphetamine Abuse and Dependence. Kitanaka N; Hall FS; Uhl GR; Kitanaka J Curr Drug Res Rev; 2019; 11(2):85-91. PubMed ID: 31875781 [TBL] [Abstract][Full Text] [Related]
13. Lithium, a potential protective drug in Alzheimer's disease. Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403 [TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. Forlenza OV; De-Paula VJ; Diniz BS ACS Chem Neurosci; 2014 Jun; 5(6):443-50. PubMed ID: 24766396 [TBL] [Abstract][Full Text] [Related]
15. Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers. Del' Guidice T; Beaulieu JM J Recept Signal Transduct Res; 2015 Jun; 35(3):224-32. PubMed ID: 26459714 [TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Gould TD; Manji HK Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567 [TBL] [Abstract][Full Text] [Related]
17. New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview. Bortolozzi A; Fico G; Berk M; Solmi M; Fornaro M; Quevedo J; Zarate CA; Kessing LV; Vieta E; Carvalho AF Pharmacol Rev; 2024 May; 76(3):323-357. PubMed ID: 38697859 [TBL] [Abstract][Full Text] [Related]
18. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Sutton LP; Rushlow WJ Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305 [TBL] [Abstract][Full Text] [Related]
19. Lithium for schizophrenia: supporting evidence from a 12-year, nationwide health insurance database and from Akt1-deficient mouse and cellular models. Luo DZ; Chang CY; Huang TR; Studer V; Wang TW; Lai WS Sci Rep; 2020 Jan; 10(1):647. PubMed ID: 31959776 [TBL] [Abstract][Full Text] [Related]
20. [Psychotropic drugs and the involvement of the Akt/GSK3 signalling pathway in mental illnesses]. Del'Guidice T; Beaulieu JM Med Sci (Paris); 2010; 26(6-7):647-51. PubMed ID: 20619169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]